UNSPSC 51101697: Bidimazium iodide

This classification denotes an antihelminthic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2D4432ZP6M. European Medicines Agency schedules Bidimazium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05823MIG.

Bidimazium iodide generally arises in the molecular formula C26H25N2S.I. The term BIDIMAZIUM IODIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 26, no. 10 1972, list 12.) Most nations schedule bidimazium iodide under HS 29341000 and SITC 51579. As of Q4 2014, BIDIMAZIUM IODIDE remains the US FDA Preferred Term for this commodity. Bidimazium iodide bears US NLM identifiers UMLS ID C2825733 and NCI Concept Code C81724. SMILES: I.s1c([n](c(c2ccc(cc2)c2ccccc2)c1)C)/C=C\c1ccc(N(C)C)cc1.

UNSPSC 51101697 Bidimazium iodide is a Commodity code that in state and local procurement practice covers pharmaceutical products and related medical supplies. Recent opportunities posted under this code show little activity directly aligned with the code's nominal scope; instead, the tagged solicitations reflect broader pharmaceutical and health-supply procurement by state health departments and county health authorities. The Illinois Department of Public Health's award to Chartwell Rx LLC covers antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride), while Seminole County, Florida's open procurement targets naloxone and drug deactivation systems for community health initiatives. State health departments and county health authorities drive the activity under this code, with procurement vehicles including cooperative purchasing consortia (such as MMCAP Infuse) and competitive invitation-for-bid processes.

Recent solicitation activity spans Illinois and Florida. The Illinois Department of Public Health completed a piggyback pharmaceutical warehouse award through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026, with a total contract value of $2,999,999.11 over the life of the three-year agreement (12-month initial term plus two renewal options). Seminole County, Florida issued an IFB (solicitation number IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly delivery to the Seminole County Community Health Building in Sanford; the response deadline was July 26, 2026, at 2:00 pm. Neither opportunity applied business enterprise or veterans set-asides, and both required standard compliance certifications including drug-free workplace and E-Verify attestation.